Chinese authorities are claiming that the order to pay bribes came right from the top of GSK's China operation. Lex's Oliver Ralph and Robert Armstrong discuss why GSK's stock has barely moved and whether this is China's opening gambit in a drive to oust corruption in its drug industry.
For more video content from the Financial Times, visit http://www.FT.com/video
Subscribe to the Financial Times on YouTube; http://goo.gl/vUQx5k Twitter https://twitter.com/ftvideo Facebook https://www.facebook.com/financialtimes
